{
    "hands_on_practices": [
        {
            "introduction": "Understanding the inheritance patterns of hereditary optic neuropathies is fundamental to genetic counseling and risk assessment for families. This practice explores autosomal dominant optic atrophy (DOA), focusing on the critical concepts of incomplete penetrance and how to update risk probabilities based on an individual's clinical status. By working through this scenario , you will develop the quantitative skills needed to translate genetic principles into precise risk figures for at-risk family members.",
            "id": "4678435",
            "problem": "A family presents with dominant optic atrophy attributed to a confirmed heterozygous pathogenic variant in the optic atrophy 1 (OPA1) gene in the proband. Assume autosomal dominant transmission, independent meioses, no phenocopies, and age-complete penetrance of $0.8$ by age $40$ for OPA1 variant carriers. The proband has three adult children: Child A, Child B, and Child C. At age $40$, Child C is clinically affected, while Child A and Child B are clinically unaffected. Child A and Child B each have exactly one biological child, both currently age $40$.\n\nUsing only the following foundational principles:\n- In autosomal dominant inheritance, a heterozygous parent transmits the pathogenic allele to each child with probability $1/2$.\n- Penetrance is the probability that an individual who carries a disease-causing allele expresses the phenotype; here this is $0.8$ by age $40$.\n- All meioses and disease expressions across individuals are independent given genotypes.\n\nDerive, from first principles and appropriate conditioning on the observed phenotypes, the probability that at least one of the two grandchildren (one from Child A and one from Child B) is clinically affected by age $40$. Express your final answer as an exact fraction. No rounding is required.",
            "solution": "The problem is assessed as valid. It is scientifically grounded in the principles of Mendelian genetics and probability theory, self-contained, well-posed, and objective. All necessary information is provided to derive a unique solution.\n\nThe objective is to calculate the probability that at least one of two specific grandchildren is clinically affected by age $40$, given the family history and phenotypes.\n\nLet us define the following events and probabilities based on the problem statement:\n- $G$: The event that an individual has the pathogenic heterozygous OPA1 genotype.\n- $g$: The event that an individual does not have the pathogenic genotype (i.e., is homozygous wild-type).\n- $A$: The event that an individual is clinically affected by age $40$.\n- $U$: The event that an individual is clinically unaffected by age $40$.\n\nFrom the problem statement, we are given the following foundational probabilities:\n1.  The proband is a heterozygous carrier ($G$). For any child of the proband, the prior probability of inheriting the pathogenic allele is $P(\\text{child has } G) = \\frac{1}{2}$, and the probability of not inheriting it is $P(\\text{child has } g) = \\frac{1}{2}$.\n2.  The penetrance of the genotype is $P(A|G) = 0.8$.\n3.  The probability of being a non-penetrant carrier (having the genotype but being unaffected) is $P(U|G) = 1 - P(A|G) = 1 - 0.8 = 0.2$.\n4.  There are no phenocopies, which means an individual without the pathogenic genotype cannot be affected. This implies $P(A|g) = 0$.\n5.  Consequently, an individual without the pathogenic genotype must be unaffected: $P(U|g) = 1 - P(A|g) = 1 - 0 = 1$.\n\nThe problem states that Child A and Child B are clinically unaffected at age $40$. We must first determine the posterior probability that Child A (and by symmetry, Child B) is a carrier of the pathogenic allele, given their unaffected status. Let us denote the event that Child A has the genotype as $G_A$ and the event that Child A is unaffected as $U_A$. We use Bayes' theorem to find $P(G_A|U_A)$:\n\n$$P(G_A|U_A) = \\frac{P(U_A|G_A)P(G_A)}{P(U_A)}$$\n\nTo find the denominator, $P(U_A)$, we use the law of total probability:\n$$P(U_A) = P(U_A|G_A)P(G_A) + P(U_A|g_A)P(g_A)$$\n\nSubstituting the known values:\n- $P(G_A) = \\frac{1}{2}$\n- $P(g_A) = \\frac{1}{2}$\n- $P(U_A|G_A) = 0.2$\n- $P(U_A|g_A) = 1$\n\nSo, the total probability of Child A being unaffected is:\n$$P(U_A) = (0.2) \\left(\\frac{1}{2}\\right) + (1) \\left(\\frac{1}{2}\\right) = 0.1 + 0.5 = 0.6$$\n\nNow we can calculate the posterior probability that Child A is a carrier, given they are unaffected:\n$$P(G_A|U_A) = \\frac{P(U_A|G_A)P(G_A)}{P(U_A)} = \\frac{(0.2) \\left(\\frac{1}{2}\\right)}{0.6} = \\frac{0.1}{0.6} = \\frac{1}{6}$$\n\nThe probability that Child A is not a carrier, given they are unaffected, is:\n$$P(g_A|U_A) = 1 - P(G_A|U_A) = 1 - \\frac{1}{6} = \\frac{5}{6}$$\nBy symmetry, the same probabilities apply to Child B: $P(G_B|U_B) = \\frac{1}{6}$ and $P(g_B|U_B) = \\frac{5}{6}$.\n\nNext, we determine the probability that the grandchild of Child A, let's call this individual GA, is clinically affected by age $40$. Let this event be $A_{GA}$. We use the law of total probability, conditioning on the genotype status of Child A:\n$$P(A_{GA}) = P(A_{GA}|G_A)P(G_A|U_A) + P(A_{GA}|g_A)P(g_A|U_A)$$\n\nLet's evaluate the conditional probabilities for the grandchild:\n- If Child A is a carrier ($G_A$), the probability that GA inherits the allele is $\\frac{1}{2}$. If GA inherits the allele, the probability they are affected is the penetrance, $0.8$. Thus, $P(A_{GA}|G_A) = \\frac{1}{2} \\times 0.8 = 0.4$.\n- If Child A is not a carrier ($g_A$), they cannot pass on the allele, so the probability of GA being affected is $0$. Thus, $P(A_{GA}|g_A) = 0$.\n\nSubstituting these values into the equation for $P(A_{GA})$:\n$$P(A_{GA}) = (0.4) \\left(\\frac{1}{6}\\right) + (0) \\left(\\frac{5}{6}\\right) = \\frac{0.4}{6} = \\frac{4}{60} = \\frac{1}{15}$$\n\nSo, the probability that the grandchild of Child A is clinically affected is $\\frac{1}{15}$. Due to the identical situation, the probability that the grandchild of Child B is affected, $P(A_{GB})$, is also $\\frac{1}{15}$.\n\nThe question asks for the probability that at least one of the two grandchildren is clinically affected. Let this event be $E = A_{GA} \\cup A_{GB}$. It is simpler to calculate the probability of the complement event, $E^c$, which is that neither grandchild is affected. Since the inheritance and expression in the two family branches (A and B) are independent events, we have:\n$$P(E^c) = P(U_{GA} \\cap U_{GB}) = P(U_{GA}) \\times P(U_{GB})$$\n\nThe probability that a grandchild is unaffected is:\n$$P(U_{GA}) = 1 - P(A_{GA}) = 1 - \\frac{1}{15} = \\frac{14}{15}$$\n$$P(U_{GB}) = 1 - P(A_{GB}) = 1 - \\frac{1}{15} = \\frac{14}{15}$$\n\nThe probability that both are unaffected is:\n$$P(E^c) = \\frac{14}{15} \\times \\frac{14}{15} = \\frac{196}{225}$$\n\nFinally, the probability of at least one grandchild being affected is $P(E) = 1 - P(E^c)$:\n$$P(E) = 1 - \\frac{196}{225} = \\frac{225 - 196}{225} = \\frac{29}{225}$$\nThis is an exact fraction and requires no rounding.",
            "answer": "$$\\boxed{\\frac{29}{225}}$$"
        },
        {
            "introduction": "A genetic diagnosis is the first step, but understanding the cellular catastrophe it triggers is key to appreciating the disease process and identifying therapeutic targets. This exercise  models the bioenergetic crisis within a single retinal ganglion cell affected by a LHON-like defect, applying principles of mass balance to quantify the rapid decline in ATP. This practice will sharpen your ability to connect a molecular defect to its dynamic, cell-level physiological consequences.",
            "id": "4678509",
            "problem": "Adenosine Triphosphate (ATP) homeostasis in a Retinal Ganglion Cell (RGC) is governed by conservation of molecular number: at steady state, ATP production equals ATP consumption, and when production is impaired, the intracellular ATP pool declines according to a mass balance. In hereditary optic neuropathies such as Leber Hereditary Optic Neuropathy (LHON), impaired Complex I function reduces mitochondrial Oxidative Phosphorylation (OXPHOS) output. Consider a single RGC under quiescent conditions with basal ATP consumption rate $C = 1.0 \\times 10^{9}$ molecules$\\cdot$s$^{-1}$. Under normal physiology the ATP production rate $P_{0}$ equals $C$, with the fraction from OXPHOS being $f_{\\mathrm{ox}} = 0.90$ and the remainder $1 - f_{\\mathrm{ox}}$ supplied by glycolysis. A LHON-like defect reduces OXPHOS output by $0.40$, such that the impaired OXPHOS contribution is scaled by $0.60$ while glycolytic contribution is unchanged.\n\nAssume the ATP pool is spatially uniform in the soma, with initial ATP concentration $[\\mathrm{ATP}]_{0} = 3.0 \\,\\mathrm{mM}$, soma cytosolic volume $V = 2.0 \\,\\mathrm{pL}$, and a critical ATP threshold $[\\mathrm{ATP}]_{\\mathrm{crit}} = 1.0 \\,\\mathrm{mM}$, below which ion homeostasis fails. Let $N_{A}$ denote Avogadroâ€™s number. Model the ATP pool dynamics by the molecular balance $\\frac{dN}{dt} = P - C$, where $N$ is the number of ATP molecules, $P$ is the production rate under impairment, and $C$ is the consumption rate.\n\nUsing these premises:\n- Compute the impaired production rate $P$.\n- Compute the net deficit $D = C - P$.\n- Compute the time $t$ required for the ATP pool to decline from $N_{0}$ to $N_{\\mathrm{crit}}$, where $N_{0} = [\\mathrm{ATP}]_{0} \\, V \\, N_{A}$ and $N_{\\mathrm{crit}} = [\\mathrm{ATP}]_{\\mathrm{crit}} \\, V \\, N_{A}$.\n\nExpress the final answer as the time $t$ in seconds and round your answer to four significant figures. Use $N_{A} = 6.022 \\times 10^{23} \\,\\mathrm{mol}^{-1}$.",
            "solution": "The problem statement has been validated and is deemed scientifically sound, well-posed, objective, and internally consistent. All necessary data and definitions are provided to arrive at a unique, meaningful solution.\n\nThe problem asks for the time $t$ it takes for the intracellular ATP concentration in a Retinal Ganglion Cell (RGC) to fall from an initial level to a critical threshold following a metabolic insult characteristic of Leber Hereditary Optic Neuropathy (LHON). The solution requires calculating the impaired ATP production rate, the resulting deficit, and then using the mass balance equation to find the time.\n\nFirst, we determine the ATP production rates under normal physiological conditions. The total production rate $P_{0}$ is given to be equal to the basal consumption rate $C$.\n$$\nP_{0} = C = 1.0 \\times 10^{9} \\text{ molecules} \\cdot \\text{s}^{-1}\n$$\nThis total production is supplied by two pathways: Oxidative Phosphorylation (OXPHOS) and glycolysis. The fraction from OXPHOS is $f_{\\mathrm{ox}} = 0.90$.\nThe normal production rate from OXPHOS is:\n$$\nP_{\\mathrm{ox},0} = f_{\\mathrm{ox}} P_{0} = 0.90 \\times (1.0 \\times 10^{9} \\text{ molecules} \\cdot \\text{s}^{-1}) = 9.0 \\times 10^{8} \\text{ molecules} \\cdot \\text{s}^{-1}\n$$\nThe normal production rate from glycolysis is the remainder:\n$$\nP_{\\mathrm{glyc},0} = (1 - f_{\\mathrm{ox}}) P_{0} = (1 - 0.90) \\times (1.0 \\times 10^{9} \\text{ molecules} \\cdot \\text{s}^{-1}) = 1.0 \\times 10^{8} \\text{ molecules} \\cdot \\text{s}^{-1}\n$$\n\nNext, we calculate the impaired ATP production rate, $P$, under the LHON-like defect. The defect reduces OXPHOS output by a factor of $0.40$, meaning the remaining output is $1 - 0.40 = 0.60$ of the original. The glycolytic contribution is stated to be unchanged.\nThe impaired OXPHOS production rate is:\n$$\nP_{\\mathrm{ox,imp}} = 0.60 \\times P_{\\mathrm{ox},0} = 0.60 \\times (9.0 \\times 10^{8} \\text{ molecules} \\cdot \\text{s}^{-1}) = 5.4 \\times 10^{8} \\text{ molecules} \\cdot \\text{s}^{-1}\n$$\nThe glycolytic production rate remains:\n$$\nP_{\\mathrm{glyc,imp}} = P_{\\mathrm{glyc},0} = 1.0 \\times 10^{8} \\text{ molecules} \\cdot \\text{s}^{-1}\n$$\nThe total impaired production rate $P$ is the sum of these two contributions:\n$$\nP = P_{\\mathrm{ox,imp}} + P_{\\mathrm{glyc,imp}} = (5.4 \\times 10^{8} + 1.0 \\times 10^{8}) \\text{ molecules} \\cdot \\text{s}^{-1} = 6.4 \\times 10^{8} \\text{ molecules} \\cdot \\text{s}^{-1}\n$$\nWith the consumption rate $C$ remaining at its basal level, the net deficit in ATP production, $D$, is:\n$$\nD = C - P = (1.0 \\times 10^{9} - 6.4 \\times 10^{8}) \\text{ molecules} \\cdot \\text{s}^{-1} = 3.6 \\times 10^{8} \\text{ molecules} \\cdot \\text{s}^{-1}\n$$\nThe dynamics of the total number of ATP molecules, $N$, in the cell soma are governed by the mass balance equation:\n$$\n\\frac{dN}{dt} = P - C = -D\n$$\nSince $D$ is a constant, we can integrate this first-order ordinary differential equation with respect to time from $t=0$ to the final time $t$, and with respect to the number of molecules from the initial number $N_0$ to the critical number $N_{\\mathrm{crit}}$:\n$$\n\\int_{N_0}^{N_{\\mathrm{crit}}} dN = \\int_{0}^{t} -D \\, dt'\n$$\n$$\nN_{\\mathrm{crit}} - N_0 = -D t\n$$\nSolving for the time $t$:\n$$\nt = \\frac{N_0 - N_{\\mathrm{crit}}}{D}\n$$\nThe initial and critical numbers of ATP molecules, $N_0$ and $N_{\\mathrm{crit}}$, are determined by their respective concentrations, the cell volume $V$, and Avogadro's number $N_A$. We must ensure consistent units.\nGiven:\nInitial concentration $[\\mathrm{ATP}]_{0} = 3.0 \\, \\mathrm{mM} = 3.0 \\times 10^{-3} \\, \\mathrm{mol} \\cdot \\mathrm{L}^{-1}$\nCritical concentration $[\\mathrm{ATP}]_{\\mathrm{crit}} = 1.0 \\, \\mathrm{mM} = 1.0 \\times 10^{-3} \\, \\mathrm{mol} \\cdot \\mathrm{L}^{-1}$\nSoma volume $V = 2.0 \\, \\mathrm{pL} = 2.0 \\times 10^{-12} \\, \\mathrm{L}$\nAvogadro's number $N_A = 6.022 \\times 10^{23} \\, \\mathrm{mol}^{-1}$\n\nThe change in the number of ATP molecules, $\\Delta N = N_0 - N_{\\mathrm{crit}}$, is:\n$$\n\\Delta N = ([\\mathrm{ATP}]_0 - [\\mathrm{ATP}]_{\\mathrm{crit}}) \\times V \\times N_A\n$$\nSubstituting the given values:\n$$\n\\Delta N = (3.0 \\times 10^{-3} \\, \\mathrm{mol} \\cdot \\mathrm{L}^{-1} - 1.0 \\times 10^{-3} \\, \\mathrm{mol} \\cdot \\mathrm{L}^{-1}) \\times (2.0 \\times 10^{-12} \\, \\mathrm{L}) \\times (6.022 \\times 10^{23} \\, \\mathrm{mol}^{-1})\n$$\n$$\n\\Delta N = (2.0 \\times 10^{-3} \\, \\mathrm{mol} \\cdot \\mathrm{L}^{-1}) \\times (2.0 \\times 10^{-12} \\, \\mathrm{L}) \\times (6.022 \\times 10^{23} \\, \\mathrm{mol}^{-1})\n$$\n$$\n\\Delta N = (4.0 \\times 10^{-15} \\, \\mathrm{mol}) \\times (6.022 \\times 10^{23} \\, \\mathrm{mol}^{-1})\n$$\n$$\n\\Delta N = 24.088 \\times 10^{8} \\text{ molecules} = 2.4088 \\times 10^{9} \\text{ molecules}\n$$\nFinally, we compute the time $t$ by dividing the total molecular loss by the deficit rate:\n$$\nt = \\frac{\\Delta N}{D} = \\frac{2.4088 \\times 10^{9} \\text{ molecules}}{3.6 \\times 10^{8} \\text{ molecules} \\cdot \\text{s}^{-1}}\n$$\n$$\nt = \\frac{24.088}{3.6} \\, \\text{s} \\approx 6.69111... \\, \\text{s}\n$$\nRounding the result to four significant figures as required by the problem:\n$$\nt \\approx 6.691 \\, \\text{s}\n$$",
            "answer": "$$\\boxed{6.691}$$"
        },
        {
            "introduction": "After diagnosing and understanding the pathophysiology of a hereditary optic neuropathy, the next step is to evaluate potential treatments based on rigorous clinical evidence. This problem  challenges you to derive the Number Needed to Treat (NNT) from the results of a hypothetical randomized controlled trial for idebenone in LHON. Mastering this calculation is essential for translating clinical trial data into meaningful metrics for patient care and public health.",
            "id": "4678460",
            "problem": "A clinical pharmacology unit is evaluating idebenone in Leber Hereditary Optic Neuropathy (LHON), a mitochondrial optic neuropathy characterized by acute or subacute central vision loss due to retinal ganglion cell dysfunction. In a double-masked, parallel-group Randomized Controlled Trial (RCT) with adequate allocation concealment, clinically meaningful visual recovery is defined a priori as a gain of at least $0.3$ in logarithm of the Minimum Angle of Resolution (logMAR) units in at least one eye over $6$ months. Assume independent, identically distributed patient-level outcomes within each arm. The control arm (placebo) shows a recovery probability of $p_{c} = 0.15$, and the idebenone arm shows a recovery probability of $p_{t} = 0.35$. Using only the basic definitions of probability, expectation, and the interpretation of the Number Needed to Treat (NNT) as the treatment group size required to yield one additional expected recovery compared with control, derive from first principles the NNT for idebenone. Provide your final answer as a single real-valued number with no units. No rounding is required; report the exact value.",
            "solution": "The problem statement is evaluated to be scientifically grounded, well-posed, objective, and complete. All necessary data and definitions are provided, and there are no internal contradictions or violations of scientific principles. The problem is therefore deemed valid and a solution can be formulated.\n\nThe task is to derive the Number Needed to Treat (NNT) from first principles, based on the provided definition and data. The givens are:\n- The probability of recovery in the control (placebo) arm, $p_{c} = 0.15$.\n- The probability of recovery in the treatment (idebenone) arm, $p_{t} = 0.35$.\n- The definition of NNT: the treatment group size required to yield one additional expected recovery compared with control.\n\nLet us formalize the outcome for a single patient using a random variable. For a patient in the treatment arm, let the random variable $X_t$ represent the outcome, where $X_t = 1$ denotes a clinically meaningful recovery and $X_t = 0$ denotes no such recovery. The probability distribution for $X_t$ is a Bernoulli distribution with parameter $p_t$.\nThe probability of recovery is $P(X_t=1) = p_t$.\nThe probability of no recovery is $P(X_t=0) = 1 - p_t$.\n\nThe expected value of the outcome for a single patient in the treatment arm, $E[X_t]$, is calculated as:\n$$E[X_t] = 1 \\cdot P(X_t=1) + 0 \\cdot P(X_t=0) = 1 \\cdot p_t + 0 \\cdot (1 - p_t) = p_t$$\n\nSimilarly, for a patient in the control arm, let the random variable $X_c$ represent the outcome. Its distribution is Bernoulli with parameter $p_c$.\nThe probability of recovery is $P(X_c=1) = p_c$.\nThe probability of no recovery is $P(X_c=0) = 1 - p_c$.\n\nThe expected value of the outcome for a single patient in the control arm, $E[X_c]$, is:\n$$E[X_c] = 1 \\cdot P(X_c=1) + 0 \\cdot P(X_c=0) = 1 \\cdot p_c + 0 \\cdot (1 - p_c) = p_c$$\n\nNow, consider a group of $N$ patients in the treatment arm. The problem states that patient-level outcomes are independent and identically distributed (i.i.d.). The total number of expected recoveries in this group is the sum of the expectations for each individual patient. Let $X_{t,i}$ be the outcome for the $i$-th patient in the treatment group.\n$$E[\\text{Total Recoveries in Treatment Group}] = E\\left[\\sum_{i=1}^{N} X_{t,i}\\right]$$\nBy the linearity of expectation, this becomes:\n$$E\\left[\\sum_{i=1}^{N} X_{t,i}\\right] = \\sum_{i=1}^{N} E[X_{t,i}] = \\sum_{i=1}^{N} p_t = N \\cdot p_t$$\n\nLikewise, for a group of $N$ patients in the control arm, the total number of expected recoveries is:\n$$E[\\text{Total Recoveries in Control Group}] = E\\left[\\sum_{i=1}^{N} X_{c,i}\\right] = \\sum_{i=1}^{N} E[X_{c,i}] = \\sum_{i=1}^{N} p_c = N \\cdot p_c$$\n\nThe number of *additional* expected recoveries in the treatment group of size $N$ compared to a control group of the same size is the difference between these two expectations:\n$$\\text{Additional Expected Recoveries} = (N \\cdot p_t) - (N \\cdot p_c) = N(p_t - p_c)$$\nThe term $(p_t - p_c)$ is known as the absolute risk reduction (ARR).\n\nThe problem defines the NNT as the specific group size, $N$, for which this number of additional expected recoveries is exactly one. Let $N = \\text{NNT}$. We set the expression for additional expected recoveries equal to $1$:\n$$1 = \\text{NNT} \\cdot (p_t - p_c)$$\n\nSolving for NNT, we derive its formula from first principles:\n$$\\text{NNT} = \\frac{1}{p_t - p_c}$$\n\nNow, we substitute the given values into this formula:\n$p_t = 0.35$\n$p_c = 0.15$\n\n$$\\text{NNT} = \\frac{1}{0.35 - 0.15}$$\n$$\\text{NNT} = \\frac{1}{0.20}$$\n$$\\text{NNT} = 5$$\n\nThus, one needs to treat $5$ patients with idebenone for $6$ months to expect one additional clinically meaningful visual recovery compared to the number of recoveries that would have occurred in a group of $5$ patients receiving placebo.",
            "answer": "$$\\boxed{5}$$"
        }
    ]
}